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A review of the literature concerning the synthesis of acyl-specific glycerophospholipids indicates that the 
known biosynthetic sequences cannot satisfactorily explain these specific acylations. New de novo and 
salvage pathways are proposed to account for the acyl composition of highly unsaturated and saturated 
glycerophospholipids. In these hypothetical pathways, de novo synthesized glycerophosphodiesters are 
postulated to be key intermediates to establish the specific acyl composition of the resulting glycero- 
phospholipids, and to be integrated with the known cytidine pathways. A re-interpretation of the 
experimental literature in terms of these postulated pathways is provided, with some methods to test these 
proposed sequences. 
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Abbreviations: Pi, orthophosphate; GP, glycerophos- 
phate; P-choline, phosphorylcholine; P-ethanolamine, 
phosphorylethanolamine; CDP-choline, cytidinediphos- 
phocholine; CDP-ethanolamine, cytidinediphospho- 
ethanolamine; CDP-serine, cytidinediphosphoserine; 
CDP-glycerol, cytidinediphosphoglycerol; CDP-DC, 
cytidinediphosphodiglyceride; GPC, glycerophosphoryl- 
choline; GPE, glycerophosphorylethanolamine; GPG, 
glycerophosphorylglycerol; GPS, glycerophosphorylse- 
rine; PA, phosphatidic acid; PC, phosphatidylcholine; 
PE, phosphatidylethanolamine; PG, phosphatidylgly- 
cerol; PGP, phosphatidylglycerophosphate; PGGP, 
phosphatidylglyceroglycerophosphate; CL, cardiolipin; 
PI, phosphatidylinositol; PS, phosphatidylserine; DG, 
sn-1,Zdiglyceride; C18:0, octadecanoate; C18:2n-6, 
9,12-octadecadienoate; C18:3n-3, 9,12,15octadecatri- 
enoate; C20:4n-6, 5,8,11,14-eicosatetraenoate; C22: 
Sn-6, 4,7,10,13,16-docosapentaenoate; C22:6n-3, 4,7, 
10,13,16,19-docosahexanoate; SAM, S-adenosylmethio- 
nine; SAH, S-adenosylhomocysteine 
1. INTRODUCTION 
Glycerophospholipids are known to display a 
remarkable degree of molecular and metabolic 
heterogeneity in mammalian tissues. Collins [l] 
was the first to demonstrate the metabolic hetero- 
geneity of glycerophospholipids more than 20 
years ago. In studies with in vivo 32Pi incorpora- 
tion into rat liver phospholipids, he was able to 
show that the most unsaturated PC and PE species 
had the highest radiospecific activities. In accor- 
dance with these observations, later studies estab- 
lished non-random acyl incorporation into glycero- 
phospholipids and the specific acyl composition 
of glycerophospholipids of various mammalian 
tissues and species [2-61. Since that time, a great 
deal of research has been dedicated to understand 
the molecular mechanism whereby the specific acyl 
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composition of glycerophospholipids is estab- 
lished. In spite of these efforts these mechanisms 
remain uncertain. This paper briefly reviews the 
present literature on the subject and proposes new 
pathways to explain the published data. 
2. THE SEARCH FOR ACYL SPECIFICITY 
2. I. Highly unsaturated phospholipid species 
Phospholipids of nervous tissue, retina, testes, 
and muscle contain particularly high levels of 
C22:6n-3 or C22:5n-6 [7-91. These observations 
motivated an active investigation to search for acyl 
transfer specificity in the known phospholipid 
biosynthetic pathways, namely the convergent PA 
[lo-121 and cytidine pathways [12-151 which 
share the sn-1,2-diglycerides (DG) as intermediates 
for the synthesis of PC and PE; however, most of 
the research to answer this question has been done 
with liver tissue. 
A search for similarities between PA, DG, PC 
and PE species in their fatty acid composition pro- 
duced negative results [ 16,171, suggesting that the 
highly unsaturated acyl composition of PC and PE 
was not determined at the level of PA synthesis. 
Even in the retina where microsomal PA contains 
about 20% C22:6n-3 [ 181, the percent of this fatty 
acid in PC and PE is about twice as high [8,9,19], 
thus suggesting that there must be other pathways 
to account for the high levels of C22:6n-3 in PC 
and PE in this tissue. In addition, some of the 
molecular species of PC and PE contain C22:6n-3 
in both positions of the GP backbone [20]. This 
unusual acyl composition has not been reported 
for any molecular species of PA. It is likely that 
the fairly high levels of C22:6n-3 found in retinal 
PA are a reflection of the acyl-CoA pool composi- 
tion, which may be determined to a large extent by 
highly selective transport of C22:6n-3 from 
plasma lipoproteins [21]. This fatty acid is known 
to be exported from the liver in plasma lipoprotein 
phospholipids [22]. 
In view of the above results, several investiga- 
tions were initiated to determine whether the DC 
specificities of the phosphorylcholinetransferase 
(EC 2.7.8.2) and phosphorylethanolaminetransfer- 
ase (EC 2.7.8.1) were enough to account for the 
acyl composition of the various molecular species 
of these phospholipids in vivo. Results obtained 
with rat liver PC and PE indicated that the 
2 
phosphorylcholinetransferase had no specificity 
for the DC species [23-251 while the phosphoryl- 
ethanolaminetransferase had a modest specificity 
towards the C22:6n-3-containing diglycerides 
[24,26,27], which only partially accounts for the 
high levels of C22:6n-3 in the sn-2 position of rat 
liver PE. Similar results were obtained with brain 
microsomes [28]. These findings led Hill and 
Lands [29] to suggest hat the in vivo specific fatty 
acid acylations might occur by acyltransferase re- 
actions with monoacyl derivatives [30,3 11. How- 
ever, experiments to test this hypothesis failed to 
show the putative specificities in rat liver PC [29, 
32,331 and PS [34]. In view of the above negative 
results some investigators tested the hypothesis of 
catabolic specificity, i.e., that phospholipases Ar 
(EC 3.1.1.32) and AZ (EC 3.1.1.4) would show 
high selectivity toward phospholipid species with 
the least unsaturated acyl moieties in the sn-2 posi- 
tion. This would therefore lead to a relative abun- 
dance of highly unsaturated species. Somewhat 
consistent with this hypothesis, Waite and Sisson 
[35] showed a higher rate of hydrolysis of C18:2n-6 
over C20:4n-6 by a purified rat liver mitochon- 
drial phospholipase AZ. However, the hydrolysis 
of C20:4n-6 was also higher than that of 
C18:3n-3. Other reports failed to show any acyl 
specificity for the phospholipase AZ hydrolysis of 
PC and PE [36,37], therefore the biological role of 
this phospholipase in terms of the above hypothe- 
sis is doubtful. 
2.2. Highly saturated phosphatidylcholine species 
In lung alveolar tissue, more than 30% of the 
phosphatidylcholines are of the dipalmitoyl class 
[38]. This disaturated PC has unique surface 
tension-lowering properties and is the major func- 
tional component of the alveolar surfactant [39]. 
Evidence suggests that this PC is synthesized in the 
type II alveolar cells, and is stored in lamellar 
bodies which are secreted into the alveolar cells. 
There it is assembled with other components into 
a pulmonary surfactant which is then secreted onto 
the alveolar surface. A major role of this surfac- 
tant is to inhibit alveolar collapse at low transpul- 
monary pressures (review [40,41]). 
As in the case of the highly unsaturated PC and 
PE species, studies with the phosphorylcholine- 
transferase from type II pneumocytes indicated 
that the cytidine pathway lacked the necessary spe- 
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cificity to form the dipalmitoyl-PC species [42,43]. 
A search for specificity in remodeling pathways 
has suggested that acylation of the lyso derivatives 
can partially account for some of the biosynthesis 
of dipalmitoyl-PC species, together with a prepon- 
derance of palmitoyl-CoA in the acyl-CoA pool 
[44-461. The lysophospholipase transacylase (EC 
3.1.1.5), on the other hand, shows no specificity 
[47,48]. However, incubations with type II pneu- 
mocyte sonicates with CDP-[14C]choline resulted 
in more than half of the label being incorporated 
into disaturated PC species [49]. So it seems that 
the choline moiety of the CDP-choline may partici- 
pate in an acyl-specific pathway for the synthesis 
of PC. Thus, a de novo pathway for the synthesis 
of the dipalmitoyl-PC must exist in addition to the 
remodelling pathway. 
2.3. Platelet-activating factor 
Another unusual PC species for which the 
biosynthetic pathway is also unknown is l-al- 
kyl-Zacetyl-sn-glycero-3-phosphorylcholine, also 
known as platelet-activating factor (PAF). This 
alkyl phopholipid has been reported to exhibit 
powerful anti-hypertensive activity [50], and ap- 
pears to be a potent platelet-activating factor [51]. 
A phosphorylcholinetransferase from various 
tissues has been reported to use the 1-alkyl-2-ace- 
tyl-sn-glycerol as the phosphorylcholine acceptor 
from CDP-choline [52]. However, the reaction is 
inhibited by DG and the activity in the spleen 
seems too high for its physiological needs for PAF 
synthesis, and is similar to that of other tissues [9]. 
Thus it is unlikely that the cytidine pathway plays 
any role in the determination of specificity for the 
synthesis of PAF. 
As in the case for other phosphatidylcholine 
species, the search for acyl specificity in the syn- 
thesis of PAF has also included the deacylation- 
reacylation pathway. Phospholipase A2 activity on 
PAF and acetylation of the lyso-PAF residue has 
been reported [53,54]. However, this acetylation 
reaction is totally inhibited by even less than 
equimolar concentration of oleyl-CoA, indicating 
that this acyltransferase lacks the necessary specifi- 
city to synthesize PAF. 
2.4. Other glycerophospholipids 
Phosphatidylinositol (PI), CL, and PS also have 
specific fatty acid compositions which cannot be 
accounted for by the known pathways. The role of 
CDP-DG as a precursor of PI and CL is well ac- 
cepted [55-571. This liponucleotide can be formed 
from PA via the enzyme CTP :phosphatidate 
cytidylyltransferase (EC 2.7.7.41). The PA moiety 
is then esterified to inositol by CDP-diglyceride: 
inositol phosphatidyltransferase (EC 2.7.8.11). 
This metabolic sequence predicts a similar acyl 
composition of PA, CDP-diglyceride, and PI. In 
vivo studies reported by Thompson and Mac- 
Donald [58], however, have shown that the high 
level of arachidonate found in CDP-DG and PI is 
not found in the total pool of PA. These authors 
have also indicated that the fatty acid profile of CL 
is very different from that of CDP-diglyceride and 
PA. 
Among several hypotheses proposed to explain 
these discrepancies in precursor-product acyl com- 
position [58], in vivo and in vitro searches for acyl 
selectivity of the phosphatidate cytidylyltransfer- 
ase have produced disappointing results [59,60]. 
Although initial studies to search for a deacyla- 
tion-reacylation cycle of CDP-diglyceride were en- 
couraging and showed the presence of an enzyme 
catalyzing the acylation of CDP-monoacylglycerol 
by arachidonyl-CoA [61], the identity of the CDP- 
diglyceride product seems uncertain (Thompson, 
W., personal communication). Therefore, the 
reactions responsible for the specific acyl composi- 
tion of PI remain unknown. A similar case is that 
for the acyl specificity of CL [58]. In respect o the 
specific fatty acid composition of PS, I have been 
unable to find any hypotheses or experimental data 
which attempt to explain the highly unsaturated 
fatty acid composition of this glycerophospholipid, 
except for the data of Holub [34]. 
3. PROPOSAL OF NEW PATHWAYS 
In view of the insufficient specificities of the 
known pathways to synthesize highly acyl-specific 
glycerophospholipids it is necessary to postulate 
new pathways. 
3.1. De novo biosynthetic path ways 
Three de novo new pathways are proposed for 
the acyl-specific synthesis of PC, PE, PI, PS, PG 
and Cl species (schemes l-3). The hypothetical 
reactions depicted are the minimum number of 
steps required, but the actual pathways may have 
3 
Volume 170, number 1 FEBS LETTERS May 1984 
2-ACYL-GPC PC (storage) **r~ PE (storage) 2-ACYL-GPE 
ACYL-WNOR 3SAH 3~~~;~~LAMINE i-"kR 
PC (acyl specific) PS (storage) PE (acyl specific) 
2-ACYL-GPS -7 GPS-TCDP-SERINE 
ACYL-DONOR ACYL-DONOR CDP GP 
PS (acyl specific) 
Scheme 1. Terminal reactions of the cytidine pathways, PE methylation, PS decarboxylation and serine exchange 
sequences, and proposed e novo pathways for the biosynthesis of acyl-specific PC, PE and PS. 
more intermediates. In the conceptual develop- 
ment of the proposed pathways, the following 
design features are included. First, in tissues which 
have the cytidine pathways these are integrated in- 
to the proposed biosynthetic pathways as sources 
of bases or alcohols, i.e., choline, ethanolamine, 
inositol, and glycerol, which are esterified by GP 
to form the corresponding GP derivatives. The 
cytidine pathways are proposed to have a primary 
role in the salvage, storage, and conservation of 
phospholipid bases or alcohols. These cytidine 
pathways may also have a role in short-term 
storage of essential fatty acid precursors, such as 
C18:2n-6 and C18:3n-3 acids. Second, the de 
novo pathways may also be integrated with plasma 
lipoprotein phospholipids in certain tissues 
4 
(scheme 2). These lipoproteins are assumed to 
transport phospholipid bases and essential fatty 
acids (both dietary precursors and desaturated and 
elongated metabolites) from the liver to peripheral 
tissues such as muscle, testes, brain, and retina. 
This is particularly important for these highly 
specialized tissues, which may have little or no ac- 
tivity of the storage-&dine pathways. Third, the 
esterification of the phospholipid bases to GP to 
form glycerophosphodiesters has a central role in 
establishing the specific acyl and alkyl composition 
of the final phospholipid species, except for that of 
PI. The postulated glycerophosphodiesters circum- 
vent the need for common acylated metabolites or 
intermediates, such as DG or CDP-DG, for the 
synthesis of specific phospholipid species. The acyl 
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Plasma lipoprotein PC- Peripheral tissue PC 
ic 
7=iPE 
GP 3SAH 3sAM 
PA 
PC(acy1 specific 2-ACYL-GPC 
TGPC 
ACY L-DONOR ACYL-DONOR 
Scheme 2. Proposed sequences for the synthesis of acyl-specific glycerophospholipids from plasma lipoprotein 
glycerophospholipids, with PC depicted as an example. 
specificity is postulated to be achieved by two 
specific acyl transferases or one acyl and one alkyl 
transferase, which would have recognition sites for 
both acyl or alkyl donors and acceptors. The first 
acyl transferase would recognize the glycerophos- 
phodiester and acylate the sn-2 position, which is 
the position found to be most specific for its acyl 
moiety. A second acyl or alkyl transferase would 
then recognize the 2-acyl-~~-glycerophosphodiester 
and acylate or alkylate the sn-1 position, forming 
the final product. Fourth, the phosphoryl group in 
the final glycerophospholipid is postulated to 
PA PI(acy1 specific 
~ 
CTP MP 
PPi 
F 
INOSITOL 
CDP-DG i storage) CDP-DG (acyl specific) 
k 
GP 
CMP F- 
ACYL-DONOR 
PGP 2-ACYL-CDP-GLYCEROL 
h 
Pi CMP DG 
~ 
ACYL-DONOR 
PG (storage) it CDP-GLYCEROL 
\ 
77+"'" 
GP CDP 
k 
ACYL-DONOR 
CL 2-ACYL-GPG 
k 
ACYL-DONORS 
k 
ACYL-DONOR 
2LACYF;-PGGP PGfacyl specific) 
Scheme 3. Proposed pathways for the biosynthesis of acyl-specific PG and PI, and their integration with the storage, 
liponucleotide sequence. 
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originate from GP and not from the phosphoryl- 
ated base, as is the case for the cytidine pathways 
for PC and PE synthesis. The GP is therefore in- 
corporated as a unit, and this could be tested by a 
GP incorporation experiment with double-labeled 
GP. Consequently, when the CDP-esters are in- 
tegrated with the proposed de novo pathways they 
do not donate the phosphorylated base as a unit 
but are only base donors for GP. 
The biosynthesis of PI is proposed to be 
achieved by an acyl-specific CDP-DG which trans- 
fers its PA moiety to inositol. This CDP-DO is 
postulated to be synthesized by two specific acyla- 
tions of CDP-glycerol (scheme 3). The synthesis of 
acyl-specific PG is proposed to proceed as for the 
other phospholipids, by specific acylations of its 
glycerophosphodiester precursor. Cardiolipin, 
however, is postulated to be synthesized from an 
acyl-specific PG via a transfer of GP from CDP- 
glycerol to this PG in a reaction analogous to that 
of phosphorylcholinetransferase. The PGGP inter- 
mediate would then be specifically acylated to 
form the final CL product (scheme 3). In these 
hypothetical pathways, PI, PG and CL do -not 
share any common acylated intermediates.’ 
3.2. Glycerophosphodiester salvage pathways 
Dawson [62] has shown that the catabolism of 
phospholipids involves the formation of glycero- 
phosphodiesters. This occurs by the combined ac- 
FATTY ACID 
I-ACYL-GPC 
2-ACYL-GPE 
~~ 
CoASH 
ACYL-DONOR 
ACYL-CoA 
,,,_/_, 
CDP-ETHANOLAMINE 
CDP GP 
TpE(storage) 
De 
4 
‘c(acy1 specific) 
Scheme 4. Proposed glycerophosphodiester recycling pathway (with GPC as an example), and fatty acid @z-2 acyl 
moiety) recycling pathway, integrated with the proposed de nova and salvage GPE sequence. 
6 
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tion of phospholipases Ar or AZ, and 
lysophospholipases Ar or AZ. The resulting gly- 
cerophosphodiesters may be further hydrolyzed to 
GP and free base by the corresponding glycero- 
phosphodiesterases [63]. I postulate that in condi- 
tions of metabolic stress, such as in choline defi- 
ciency, the catabolism of acyl-specific phospho- 
lipids is decreased, and the glycerophosphodiester- 
ase activities are decreased, to allow an increased 
molar fraction of the catabolic phosphodiesters to 
be reutilized or recycled to form specific glycero- 
phospholipids. Tissues which have low activities of 
the base conservation-storage pathways (i.e., the 
cytidine pathways), or are devoid of them, should 
have very low phosphodiesterase activities. This 
would allow for a high flux of reutilization of gly- 
cerophosphodiesters. 
Two salvage pathways are proposed (scheme 4), 
particularly for GPC, which includes a recycling of 
C22:6n-3 from PC turnover by phospholipases. In 
these proposed salvage pathways, part of the PE 
pool is considered to have a reservoir role for 
C22:6n-3, and other important fatty acids, for 
other glycerophospholipids uch as PC. These fat- 
ty acids may be transferred from PE singly or as 
diglyceride units. 
The glycerophosphodiester ecycling pathway 
may be segregated from the de novo GPC pathway 
(which may be in a different organelle) to allow in- 
dependent control of the glycerophosphodiesters 
according to their metabolic origin or location. An 
alternative way to control the catabolism of the 
phosphodiesters may entail the design of a high-K,,, 
phosphodiesterase operating on a single pool of 
glycerophosphodiesters. Catabolic activity would 
be high only above a certain concentration of the 
particular phosphodiester. Unique fatty acids such 
as C22:6n-3 resulting from the phospholipase or 
lysophospholipase turnover of the functionally ac- 
tive glycerophospholipids, such as PC, would then 
be conserved by reacylation into PE via de novo or 
recycled GPE, or acylation of the l-acyl-sn- 
glycerophosphorylethanolamine. In addition, diet- 
ary C22:6n-3 would be stored in PE via the 
cytidine salvage-conservation pathway through the 
somewhat C22:6n-3-specific phosphorylethanol- 
aminetransferase reaction. These conservation 
pathways may be responsible for the tenacious 
retention of C22:6n-3 observed by Tinoco et al. 
[8] in C18:3n-3-deficient rats. 
4. RE-INTERPRETATION OF LITERATURE 
DATA ACCORDING TO THE PROPOSED 
PATHWAYS 
4.1. Precursor-product studies 
The demonstration, in early studies, that GPC 
and GPE could be isolated from mammalian 
tissues [63-661 suggested the hypothesis that these 
glycerophosphodiesters might be intermediates in 
the synthesis of PC and PE, respectively. The 
availability of the analysis of precursor-product 
data from pulse-chase xperiments, according to 
the criterion proposed by Zilversmit et al. [67], 
prompted its use to test the above hypothesis. 
Ansell and Norman [66], in experiments with rat 
brain, observed that after the intraperitoneal or in- 
tracisternal injection of 32Pi the specific activity of 
brain GPE was always greater than that of PE dur- 
ing a 24-h chase. Similar results were obtained 
by in vitro incubations. The authors, however, 
concluded that a biosynthetic pathway involving 
GPE as a possible intermediate was unlikely to be 
a major pathway. They concluded this because the 
difference in specific activity between GPE and PE 
was not large enough considering the small pool 
size of GPE and the higher specific activity ob- 
served in P-ethanolamine. However, if the im- 
mediate precursors of P-ethanolamine and GPE 
are not the same, and the specific activity of the 
GPE precursor is lower than that of the P-ethanol- 
amine precursor (scheme l), then these data are 
compatible with the hypothesis that the proposed 
de novo pathway carries a large fraction of the 
biosynthetic flux for PE synthesis in this tissue. In 
this pathway the immediate 32P-labelled precursor 
for GPE and GPC is GP, while that for phosphor- 
ylcholine and phosphorylethanolamine is ATP. 
The specific activity of GPE will be much lower 
than that of P-ethanolamine because most of the 
GP pool is derived from the glycolytic pathway 
[68]. The fairly large pool sizes of the 4 
phosphorylated glycolytic intermediates between 
ATP and GP, plus several convergent and diver- 
gent branches, will greatly decrease the 32P specific 
activity of GP with respect to P-ethanolamine. 
Therefore, when the specific activity of the total 
pool of PE is determined, as Ansell and Norman 
did, the molecular species of PE synthesized by the 
cytidine pathway will contribute more radio- 
activity to total PE than their share of the biosyn- 
7 
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thetic flux. Since I propose that the de novo GPE 
pathway has a role to synthesize specific molecular 
species of PE, the high levels of C20:4n-6 and 
C22:6n-3 PE species formed in the brain [69] will 
require a high biosynthetic flux through the de 
novo GPE pathway, at least during growth and 
development. In the adult, the requirements for de 
novo synthesis may be less if they are mostly deter- 
mined by slow turnover rates, which may utilize 
glycerophosphodiester recycling pathways. 
Similar precursor-product experiments reported 
by Dawson [62] in rat liver failed to confirm the 
data for the brain reported by Ansell and Norman 
[66]. Rather, Dawson’s data showed lower specific 
activities for GPE than PE, and thus was consis- 
tent with GPC and GPE being catabolic products 
of their respective glycerophospholipids. The in- 
consistency between the brain and liver experi- 
ments can readily be understood if one assumes 
that the biosynthetic flux of the cytidine pathway 
in the liver is much higher than that of the de novo 
GPC and GPE pathways, and that the catabolic 
flux of GPC and GPE in the liver is higher than 
that in the brain. When this is coupled with a 
higher 31P specific activity of the cytidine-origina- 
ted PC and PE than that originated by the de novo 
GPC and GPE pathways, the invisibility of the 
latter pathway by the pulse-chase method is ex- 
pected when the specific activity of the total pools 
of PC and PE vs GPC and GPE are being 
measured. Reiner [70] has written a lucid discus- 
sion of other metabolic conditions which do not 
comply with the precursor-product criterion of 
Zilversmit et al. [67]. 
increase in the intermediates of the cytidine 
pathway for PE synthesis in choline-methionine 
deficiency [72], it may be inferred that the in- 
creased flux through this pathway may be partially 
responsible for the higher levels of C22:6n-3 PE. 
This is possible because the phosphorylethanol- 
aminetransferase has some specificity for the hexa- 
enoic diglycerides [24,26,27]. More significant, 
however, is a 3-fold increase in GPE concentra- 
tions seen in choline-methionine deficiency [72]. In 
agreement with the earlier report of Dawson [62], 
pulse-chase studies with [14C]ethanolamine with 
the choline-methionine sufficient animals showed 
lower specific activity of GPE when compared to 
that of PE at all times of the chase [72]. In the 
choline-methionine deficient animals, however, 
the specific activity of GPE was higher than that of 
PE in the early chase times. These data support the 
proposed pathway whereby GPE is a precursor of 
PE. I postulate that the major reason for the in- 
creased flux through the PE-cytidine pathway is to 
provide CDP-ethanolamine for the de novo acyl- 
specific GPE pathway (scheme 1). I suggest hat in 
the choline-methionine deficient animals the GPE 
pathway becomes visible by the pulse-chase tech- 
nique because of its greatly increased flux. This 
hypothesis is further consistent with the fact that 
the C22:6n-3 PE species account for most of the 
increased biosynthetic flux, since the proposed 
GPE pathway is largely responsible for the syn- 
thesis of this highly unsaturated PE species. 
4.2. GPC-recycling and fatty acid salvage- 
conservation pathways 
A condition which greatly decreases the flux of I suggest hat an additional reason for the in- 
PC synthesis via the cytidine pathway, in the liver, crease in the de novo GPE pathway in the choline- 
is a choline-methionine deficient diet. Such a methionine deficient state is to activate the GPC 
dietary manipulation can produce a nearly 5-fold recycling pathway (scheme 4). By this mechanism, 
decrease in the P-choline concentration in rat liver the catabolically originated GPC (the flux of which 
[71,72]. If choline kinase (EC 2.7.1.32) catalyzes should also be decreased by the deficiency) is 
the flux-generating step of this cytidine pathway salvaged by re-acylation by the C22:6n-3 PE. In 
[73-751, then a similar decrease in this biosynthetic addition, the GPC phosphodiesterase activity 
flux to PC should occur. Since PC can also be syn- should be decreased by the deficiency to maximize 
thesized via the sequential methylation of PE 1761, GPC’s reutilization. The postulation of a de- 
a compensatory increase in the synthesis of PE oc- creased catabolic production of GPC, concomitant 
curs. This leads to its accumulation because the with a decrease in GPC phosphodiesterase in the 
concomitant methionine deficiency impairs the deficient state, is consistent with the observation 
methylation of PE to PC 1771. Most of the expan- that the liver pool size of GPC in the deficient 
sion of the PE pool is due to an increase in the animals is not significantly different from that of 
C22:6n-3 species of PE [77]. Since there is a large the control animals [72]. This hypothesis predicts 
8 
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that a pulse-chase study with 32Pi in choline- 
methionine deficient animals should show a 
precursor-product relationship for the GPC-PC 
pair, since the cytidine pathway and catabolic pro- 
duction of GPC should be drastically decreased by 
this dietary condition. The GPC-recycling pathway 
should also become visible by the pulse-chase 
technique under this dietary deficiency. 
There are other data consistent with the de- 
creased catabolic production and increased reuti- 
lization of GPC in the choline-methionine defi- 
cient state. GPC is known to be present in high 
concentrations in sheep liver [78], which also 
has extremely low GPC phosphodiesterase (EC 
3.1.4.2) activity [79], and very low choline oxida- 
tion rates as well [80]. Moreover, dietary choline is 
almost totally degraded in the sheep rumen by 
microbial demethylation [8 11, which is consistent 
with the finding that long-term feeding of labelled 
choline produced only insignificant labelling of 
plasma PC [82]. Therefore the sheep, and perhaps 
other ruminants as well, may normally have a 
functional dietary choline deficiency. I postulate 
that, in addition to the high flux of PE methylation 
observed in the liver of this species [BO], the sheep 
does not develop signs of choline deficiency 
because it has a high flux of the de novo acyl- 
specific GPC pathway and uses the PC synthesized 
from PE methylation as a choline donor for GP 
(scheme 2), and that the sheep also has a high flux 
of GPC recycling (scheme 4). Therefore, the sheep 
liver should be a very good tool to study the de 
novo GPC pathway, as well as the GPC salvage 
pathways. 
Data consistent with the proposed conservation- 
salvage pathway of C22:6n-3 (scheme 4) are 
reported by Tinoco et al. [83]. These authors show- 
ed that hexaenoic PE incorporated and lost la- 
belled ethanolamine rapidly. Despite a small pro- 
portion of C22:6n-3 in the diglycerides, the rat 
livers incorporated a large fraction of the label into 
C22:6n-3 PE species. Estimations of the rate of 
loss of radioactivity in the C22:6n-3 PE and its ap- 
pearance in the C22:6n-3 PC indicated that the 
docosahexaenoic acid is conserved, possibly by 
reincorporation into PE after becoming part of the 
hexaenoic PC species. The tenacious conservation 
of C22:6n-3 in C18:3n-3-deficient rats [8] is con- 
sistent with the proposed conservation schemes. 
4.3. Connections with the cytidine pathways 
The cytidine sequences for PC and PE synthesis 
have unusual thermodynamic profiles and asso- 
ciated kinetic properties. The first two reactions, 
catalyzed by the kinases and cytidylyltransferases, 
are far from equilibrium, while the last transfer of 
the phosphorylated base to the diglyceride is near 
equilibrium [73]. This reaction lacks the far-from- 
equilibrium directional force normally seen in the 
final reaction of biosynthetic pathways. Computer 
simulations with a thermodynamic design of this 
type show a kinetic behavior which tends to main- 
tain a constant concentration of the cytidine inter- 
mediates, i.e., CDP-choline and CDP-ethanol- 
amine (unpublished). Consistent with this kinetic 
property is the fact that the liver pool size of CDP- 
choline is by far the least affected by a choline- 
methionine deficient diet [71,72,84]. In addition, 
when rat hepatocytes are subjected to increasing 
concentrations of ethanolamine, they maintain a 
nearly constant CDP-ethanolamine concentration, 
whereas the pool sizes of ethanolamine and P-etha- 
nolamine are drastically increased [85]. Simulation 
studies of the cytidine pathway for PC synthesis, at 
various levels of choline, show that at normal 
cellular concentrations of choline the pool size of 
CDP-choline is maintained by a forward net flux 
through the two far-from-equilibrium reactions 
catalyzed by choline kinase and the corresponding 
cytidylyltransferase (EC 2.7.7.15). In the choline- 
methionine deficient state, however, the level of 
CDP-choline is maintained by a net reverse flux of 
the phosphorylcholinetransferase, with the far- 
from-equilibrium condition of the first two steps 
assuring that the net flux is reversed only up to the 
CDP-choline intermediate (unpublished). I con- 
clude that CDP-choline and CDP-ethanolamine 
must have fundamental metabolic roles other than 
being only intermediates of the cytidine pathway. 
I suggest that the PC and PE species of the cytidine 
pathway may act as reservoirs of choline or 
ethanolamine units to form the donor species 
(CDP-choline or CDP-ethanolamine) for the de 
novo GPC and GPE pathways (scheme 1). The 
cytidine PC and PE species may act as reservoirs of 
dietary essential fatty acids as well. 
Since the phosphorylcholinetransferase r action 
is near equilibrium, the flux will be very sensitive 
to changes in the mass action ratio of the reactants 
involved [73]. A rise in cytosolic CMP will increase 
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the net reverse flux in the direction of CDP-choline 
synthesis, which is then channelled into the GPC 
pathway. Quirk et al. [86] have studied the tem- 
poral relationships between the various lung 
developmental changes and the pool sizes of 
several cytidine metabolites in rabbit lung. Up to 
day 26 of gestation there is an increased concentra- 
tion of CDP-choline coupled with a decrease in the 
size of the CTP pool, while the CMP concentra- 
tion remains relatively constant. From day 26 to 
adulthood there is a drastic decrease in CDP- 
choline coupled with a 4-fold increase in CMP con- 
centration, whereas the level of CTP remains 
relatively constant. I propose that these changes 
are due to an increase in the forward net flux of the 
cytidine pathway as a temporary storage of choline 
up to about day 26 of gestation. After this time, 
the specific GPC pathway for the synthesis of 
dipalmitoyl-PC surfactant is turned on using CDP- 
choline as a choline donor for GP (scheme 1). At 
this stage an increased fraction of the CDP-choline 
is produced by a reversal of the phosphorylcholine- 
transferase reaction of the cytidine pathway by an 
increase in the CMP concentration, in addition to 
being produced by the forward net flux from 
choline to CDP-choline. Hence, the increased syn- 
thesis of CMP and the activation of the de novo 
GPC pathway are likely to be the initial responses 
to the hormonal signals responsible for the activa- 
tion of the lung surfactant synthesis necessary for 
lung maturation. Mandel and Edel-Harth [87] 
found a similar increase in the concentration of 
CMP coupled with low CDP-choline and CDP- 
ethanolamine levels in the brains of l-day old rats. 
These nucleotide concentrations are associated 
with a high growth rate of the brain at this stage 
[69]. I suggest hat these nucleotide ratios in the 
brain are also due to the activation of the de novo 
GPC and GPE pathways for the synthesis of the 
C22:6n-33 PC and PE species which are being 
deposited at high levels in the developing brain, 
particularly in the gray matter [69]. At this devel- 
opmental stage a large fraction of the base donors, 
i.e., CDP-choline and CDP-ethanolamine, may 
originate from the reversal of the terminal reaction 
in each of the cytidine pathways by the increased 
concentration of CMP. Upon lactation, dietary 
choline then restores the forward flux of the 
cytidine pathway for choline and ethanolamine 
storage. 
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Other evidence compatible with the proposed 
connection between the cytidine pathways and the 
de novo glycerophosphodiester pathways comes 
from the analyses of phospholipid metabolites in 
growing cell cultures. Activation of quiescent 
Swiss 3T3 mouse fibroblasts by serum has been 
reported to be accompanied by 3-fold increases of 
P-choline, P-ethanolamine, and their glycerophos- 
phodiesters [88]. Similar findings have been 
reported for other cell lines, including cancer cells 
[89-911. Since high rates of phospholipid 
catabolism are unlikely in rapidly growing cells, I 
suggest hat a large fraction of the glycerophos- 
phodiester pools, in these cells, originates from 
their de novo synthesis for the manufacture of the 
corresponding acyl-specific phospholipid species. 
In the case of the specific acyl composition of 
PI, the hypothetical metabolic sequence proposed 
in scheme 3, and its connection with the cytidyl- 
liponucleotide pathway, also explains the literature 
data. An acyl-specific pool of CDP-DG formed by 
specific acylation, i.e., with C20:4n-6 and C18:0, 
of the de novo synthesized CDP-glycerol explains 
the similar acyl composition of the liponucleotide 
and PI (both of which are different from that of 
PA) reported by Thompson and MacDonald [58]. 
I suggest hat the total liponucleotide pool is com- 
posed in large part of the acyl-specific species, and 
a minor fraction comes from the non-specific 
liponucleotide pathway connected to the PA pool. 
The difference in fatty acid composition of CL and 
the liponucleotide, also reported by the above 
authors, is explained by the pathway proposed in 
scheme 3. In this hypothetical sequence the CDP- 
glycerol transfers the glycerol moiety to GP to 
form glycerophosphorylglycerol (GPG) in a reac- 
tion similar to that proposed for the de novo GPC 
and GPE synthesis (scheme 1). This glycerophos- 
phodiester is then specifically acylated to form the 
proper phosphatidylglycerol (PG) species. In 
mitochondria, a GP moiety is then transferred 
from CDP-glycerol to PG to form the intermediate 
phosphatidylglyceroglycerophosphate (PGGP), 
which is specifically acylated to form cardiolipin. 
Thus, in these proposed pathways, CDP-DG does 
not function as a source of acyl groups for the syn- 
thesis of PG or CL. 
Hubscher et al. [92] were the first to report that 
the incorporation of labelled serine into mitochon- 
drial phospholipids was increased by CMP, ATP, 
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CoASH, GP, and Mg’+, whereas CTP was less ef- 
fective than CMP and was inhibitory at higher 
concentrations. These data were corroborated by 
later reports [93-951, which showed that stimula- 
tion by GP did not occur in the absence of CMP. 
Since the phosphatidyltransferase has been shown 
to exchange CMP with CDP-diglyceride, and 
serine with PS [96], the enzyme may follow a ping- 
pong kinetic mechanism. Therefore, the stimula- 
tion of serine incorporation by CMP may be pro- 
duced by this enzymatic substitution-catalyzed ex- 
change, which may also show a phospholipase D- 
like activity by hydrolysis of the probably-unstable 
phosphatidyl-enzyme form. However, stimulation 
by CoASH, ATP, and GP cannot be explained by 
this mechanism. The need for these reactants is ex- 
plained by the pathway postulated in scheme 1. 
This sequence proposed the formation of CDP- 
serine by a CMP-dependent phosphorylserine 
transfer from the non-acyl-specific PS pool de- 
rived from the base-exchange reaction of PE, 
similar to the phosphorylcholinetransferase r verse 
reaction. The serine moiety is then further trans- 
ferred to GP to form glycerophosphorylserine 
(GPS), which is then acylated by acyl-specific acyl- 
transferases to synthesize the acyl-specific PS. 
Although attempts to isolate labelled CDP-serine 
have not been successful in pulse-chase experi- 
ments with labelled serine [97], this may be so 
because CMP was not added to the incubation 
medium. Baranska [95] also searched for a mecha- 
nism to explain the ATP-dependent, and CoASH-, 
GP-, and CMP-stimulated incorporation of la- 
belled serine into mitochondrial PS. She concluded 
that none of the known pathways of PS biosyn- 
thesis could explain the data. Among several 
hypotheses which were tested, she ruled out the 
CDP-serine pathway on the basis that no radioac- 
tivity from ~,T-‘~P]ATP was recovered in PS. The 
pathway that I propose explains these data as well, 
since the 32P label appearing in PS does not 
originate from CDP-serine, but from GP. In the 
experiments reported by Baranska [95], unlabelled 
GP was part of the experimental protocol, so that 
any endogenous phosphorylation of endogenous 
glycerol by labelled ATP would be trapped by 
isotope dilution. ATP was then required only for 
acyl-CoA synthesis for specific acylation of GPS, 
and the label from [32P]ATP would not be incor- 
porated into CDP-serine. One direct approach to 
test the postulated pathway for the synthesis of 
acyl-specific PS (scheme 1) might include the use 
of labelled GP and/or labelled CMP in the pro- 
tocol design. 
4.4. In vivo incorporation studies with labelled 
choline and phosphate 
A fundamental prediction of the cytidine 
pathway for the synthesis of PC is that the ratio of 
labelled choline and phosphate incorporated into 
this phospholipid should be equal to that of the P- 
choline precursor, since in this pathway the phos- 
phorylated base is incorporated as a unit into the 
PC product. An analogous prediction is also valid 
for the synthesis of PE via the cytidine pathway. A 
corollary of this prediction is that the isotope in- 
corporation and label ratio of choline vs phosphate 
should be equal for all the molecular species of PC 
and PE when measured before catabolism occurs, 
if they are synthesized via the cytidine pathways. 
The de novo GPC and GPE pathways, on the 
other hand, predict that the label ratios of choline/ 
phosphate found in PC and PE should be higher 
than that of P-choline and P-ethanolamine, 
respectively, for the phosphoglyceride species syn- 
thesized by these pathways. As indicated before, 
this is because the 32P specific activity of GP will 
be lower than that of P-choline. 
The operation of de novo pathways other than 
the cytidine sequences was first suggested from the 
studies of Balint et al. [98] who found higher 
choline/phosphate label ratios for hepatic tetra- 
enoic PC than for the dienoic species. These ratios 
were also higher for mitochondrial than for micro- 
somal PC. These and other data led these authors 
to suggest hat choline could be incorporated into 
PC via a pathway independent of CDP-choline. 
Studies reported by Treble et al. [99] showed that 
the label ratio of choline/phosphate in PC was 
much higher than that of P-choline. In agreement 
with Balint et al. [98], this ratio was higher for the 
arachidonoyl than for the linoleoyl species. On this 
basis, Treble et al. [99] suggested the existence of 
an unknown de novo pathway for PC synthesis in- 
volving a source of phosphate with a specific ac- 
tivity much lower than that of the phosphate of P- 
choline, or that choline was entering PC by base 
exchange. Since Dils and Hubscher [loo] had 
demonstrated that such an exchange occurs in 
vitro, this was the preferred hypothesis. Similar 
11 
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results and interpretations were reported by others 
[101,102]. However, Bjerve and others [103-1051 
have shown that in vivo operation of the base- 
exchange mechanism for PC and PE synthesis is 
negligible. 
The above results are predicted by the proposed 
pathway (scheme l), since the specific activity of 
the phosphate moiety of GP will be much lower 
than that of the phosphate moiety of P-choline 
because of dilution of the former by the larger pool 
of glycolytic intermediates. 
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